Mounjaro Weight Loss Drug update June 2025

Posted by: Editor-Putnoe - Posted on:

NHS England has announced that Mounjaro will slowly be rolled out to patients across the country to help with weight loss.

Unfortunately the roll out will take place over the next 3 years.

Initially only patients with a BMI of 40 or more AND 4 of the following health conditions will be eligible:

  • Type 2 Diabetes
  • High Blood Pressure
  • Heart Disease
  • Obstructive Sleep Apnoea
  • Abnormal Blood Fats

PLEASE DO NOT CONTACT US TO REQUEST MOUNJARO UNLESS YOU ARE ALREADY BEING PRESCRIBED IT because we are still waiting to hear from our local health commissioners as to how the service that will prescribe and monitor Mounjaro will look.

Below is some further information from the NHS press briefing.

Just how big a problem is obesity for the NHS?
Around 29% of adults in the UK,3 in 10 of us are living with obesity. It’s a complex condition which can have a significant impact on health and wellbeing for people living with it. These figures have been going in wrong direction globally for too long now, obesity rates and all the health conditions associated with it, such as diabetes and heart attacks are continuing to rise, so a new approach is needed.

Why not just give out weight loss drugs to more people?
Given the demand we expect and to ensure fairer access to treatment for patients across the country, access to tirzepatide (or Mounjaro) via the NHS for the management of obesity will be prioritised for those at greatest risk of ill health or who are experiencing severe ill health due to living with obesity.


If obesity is such a problem and these drugs work, surely the more people who are able to get these drugs the better?
These are no silver bullet, and to ensure that weight loss is safe and sustainable, it requires structured wrap around support focused on good nutrition for health and increasing physical activity, which the NHS will offer alongside the medicines. These medicines can be harmful if prescribed without the right checks and wraparound care; they can have side effects, including nausea, dehydration and inflammation of the pancreas and a worrying number of people are continuing to access them without appropriate checks via the internet.

But why can’t the NHS roll them out more quickly?
Right now, obesity is estimated to cost the NHS approximately £11.4 billion every year, this financial impact is unsustainable for the NHS and wider economy. We have to turn the tide. We have to and will go further, and faster.
We are ambitious and determined to explore different methods of delivery and strengthen the evidence base and will do so alongside this phased roll out, but this is a historic first step in widening access, with 220,000 people set to benefit from the rollout over the first three years.